Our goal is to be the leading biopharmaceutical company developing and marketing therapies that restore function and improve the lives of people with neurological disorders.

Click on a compound in development for more information.
Therapy THERAPEUTIC AREA Phase 1 Phase 2 Phase 3
BTT1023 (timolumab)
Primary Sclerosing Cholangitis (PSC)
 
 
 
CVT-427
Migraine
 
 
 
rHlgM22
MS